top of page
Blog Posts
Search
Carl Kestens
Mar 8, 20226 min read
NFL AS A HIGHLY RELEVANT BIOMARKER IN AD AND OTHER NEUROLOGICAL DISEASES
What is neurofilament-light chain (NfL)? Neurofilaments, the larger group to which NfL belongs, are structural components of neuronal...
358 views0 comments
Carl Kestens
Feb 26, 20228 min read
TIML/INKMUNE MAY DRASTICALLY OUTPERFORM CIML – A COMPARISON
Reminder of the NK cell activation threshold as a predictor of survival This, we know. · INKmune generates memory-like NK cells in...
243 views2 comments
Carl Kestens
Feb 20, 202216 min read
INKMUNE AS A NEW APPROACH IN NK-TARGETING IMMUNO-ONCOLOGY
Summary: INKmune is an NK-targeting immuno-oncology drug allowing treatment in a wide range of NK-related cancers; INKmune’s production...
425 views4 comments
Carl Kestens
Jan 23, 202213 min read
THE TEN BILLION UNICORN IN INMB: ON MY INVESTMENT THESIS AND INMB’s PRICE MOVEMENTS
In my mind's eye, these stairs keep on going into 2023 and the years after. INTRODUCTION The previous five blogs have laid out the...
433 views4 comments
Carl Kestens
Dec 29, 202110 min read
THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART IV: A DEEPER DIVE INTO INKMUNE
The immuno-oncology platform INKmune of INmune Bio may be a better, easier to produce and cheaper product candidate than others.
487 views0 comments
Carl Kestens
Dec 21, 202114 min read
THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART III: AN INTRODUCTION TO INKMUNE
INTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....
746 views1 comment
Carl Kestens
Dec 17, 202111 min read
THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART II
Drug XPro of INmune Bio has limitless potential in neurodegenerative diseases such as Alzheimers, ALS, MS, Huntington's, Parkinson's, ...
605 views0 comments
bottom of page